Ubiquinone Q2 API Manufacturers & Suppliers
0 verified results
All Ubiquinone Q2 data. Full access. Full negotiation power
Commercial-scale Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Ubiquinone Q2 | CAS No: 606-06-4 | GMP-certified suppliers
A medication that supports mitochondrial function and cellular bioenergetics through electron transport chain activity, primarily intended for research and experimental use in metabolic studies.
Therapeutic categories
Product Snapshot
- Ubiquinone Q2 is an oral small molecule formulation
- It is primarily utilized for research in energy metabolism and mitochondrial function
- The compound is currently experimental and not approved by major regulatory agencies
Clinical Overview
Although Ubiquinone Q2 is not associated with specific clinical indications and remains classified as experimental, ubiquinones in general function as essential components of the mitochondrial electron transport chain. They facilitate electron transfer between complexes I/II and complex III, thereby contributing to adenosine triphosphate (ATP) synthesis through oxidative phosphorylation. The precise pharmacodynamics and mechanism of action for Ubiquinone Q2 have not been explicitly characterized, but it is presumed to act similarly to other coenzyme Q analogues.
Pharmacokinetic data specific to Ubiquinone Q2 are limited. Generally, ubiquinones exhibit lipophilic properties influencing their absorption and distribution within biological membranes, and are subject to hepatic metabolism and biliary excretion. The safety profile has not been fully established for Ubiquinone Q2, with toxicity parameters remaining undocumented due to its experimental status. Caution is advised when handling or evaluating this compound owing to incomplete data on potential adverse effects.
Ubiquinone Q2 is primarily utilized in research settings, studying its role in enzymatic processes and mitochondrial function. It does not currently hold marketing authorizations and is not available as a therapeutic agent marketed under brand names.
From a sourcing perspective, procurement of Ubiquinone Q2 for pharmaceutical applications requires stringent quality control to ensure chemical purity, stability, and absence of impurities that may interfere with experimental outcomes. Suppliers should provide comprehensive certificates of analysis and comply with relevant regulatory guidelines to support investigative use.
Identification & chemistry
| Generic name | Ubiquinone Q2 |
|---|---|
| Molecule type | Small molecule |
| CAS | 606-06-4 |
| UNII | I7T5V2W47R |
| DrugBank ID | DB08690 |
Pharmacology
Targets
| Target | Organism | Actions |
|---|---|---|
| Succinate dehydrogenase flavoprotein subunit | Escherichia coli (strain K12) | |
| Succinate dehydrogenase iron-sulfur subunit | Escherichia coli (strain K12) | |
| Succinate dehydrogenase cytochrome b556 subunit | Escherichia coli (strain K12) |
Formulation & handling
- Ubiquinone Q2 is a small molecule, suitable primarily for oral formulation due to its low water solubility.
- The compound's moderate lipophilicity (LogP 3.88) indicates potential need for solubilization strategies in formulation.
- Stable in solid state, Ubiquinone Q2 requires handling conditions that minimize exposure to light and oxygen to prevent degradation.
Regulatory status
Ubiquinone Q2 is a type of Antidotes, Deterrents, and Toxicologic Agents
Antidotes, Deterrents, and Toxicologic Agents are an important category of pharmaceutical Active Pharmaceutical Ingredients (APIs) that play a critical role in healthcare and toxicology. These substances are designed to counteract the effects of poisons, toxins, and overdoses, thereby saving lives and preventing severe health consequences.
Antidotes are substances that neutralize the toxic effects of certain drugs, chemicals, or poisons. They work by either directly binding to the toxic substance or by blocking its harmful actions on the body. Antidotes are administered in emergency situations to quickly reverse the effects of poisoning and restore normal physiological functions.
Deterrents, on the other hand, are pharmaceutical agents used to discourage or prevent harmful behaviors, such as substance abuse. They are designed to make the ingestion or misuse of certain substances unpleasant or less desirable. Deterrents can be formulated to cause unpleasant side effects, such as nausea or vomiting, when a particular substance is consumed in excessive amounts.
Toxicologic agents encompass a broad range of pharmaceutical APIs used in toxicology studies and research. These substances are employed to investigate the toxicity, metabolism, and mechanisms of action of various chemicals and compounds. Toxicologic agents are vital for understanding the potential hazards and risks associated with certain substances, ensuring the safety of drugs, and developing effective treatments for poisoning cases.
In conclusion, Antidotes, Deterrents, and Toxicologic Agents are essential categories of pharmaceutical APIs that address poisoning emergencies, deter harmful behaviors, and enable toxicological research. Their development and availability are crucial for safeguarding public health, enhancing patient care, and advancing our understanding of toxicology.
